Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Marimed (MRMD) EBIT Margin (2016 - 2025)

Marimed (MRMD) has disclosed EBIT Margin for 15 consecutive years, with 3.94% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin rose 62.0% to 3.94% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.3%, a 396.0% decrease, with the full-year FY2024 number at 1.84%, down 784.0% from a year prior.
  • EBIT Margin was 3.94% for Q3 2025 at Marimed, up from 2.88% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 36.85% in Q2 2021 to a low of 3.62% in Q4 2024.
  • A 5-year average of 10.64% and a median of 8.48% in 2023 define the central range for EBIT Margin.
  • Biggest YoY gain for EBIT Margin was 1507bps in 2021; the steepest drop was -3561bps in 2021.
  • Marimed's EBIT Margin stood at 3.88% in 2021, then soared by 122bps to 8.62% in 2022, then decreased by -28bps to 6.2% in 2023, then plummeted by -158bps to 3.62% in 2024, then surged by 209bps to 3.94% in 2025.
  • Per Business Quant, the three most recent readings for MRMD's EBIT Margin are 3.94% (Q3 2025), 2.88% (Q2 2025), and 2.24% (Q1 2025).